Pfizer Inc. (NYSE:PFE) Shares Sold by Forsta AP Fonden

Forsta AP Fonden cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,383,500 shares of the biopharmaceutical company’s stock after selling 37,900 shares during the period. Forsta AP Fonden’s holdings in Pfizer were worth $36,704,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in PFE. AQR Capital Management LLC lifted its stake in Pfizer by 1.6% during the second quarter. AQR Capital Management LLC now owns 612,429 shares of the biopharmaceutical company’s stock worth $17,068,000 after purchasing an additional 9,435 shares in the last quarter. Magnolia Capital Advisors LLC purchased a new stake in shares of Pfizer in the 2nd quarter valued at $409,000. Quarry LP acquired a new position in Pfizer during the 2nd quarter worth about $31,000. IMS Capital Management grew its position in Pfizer by 2.0% in the 2nd quarter. IMS Capital Management now owns 104,938 shares of the biopharmaceutical company’s stock valued at $3,033,000 after acquiring an additional 2,029 shares in the last quarter. Finally, Heartland Bank & Trust Co purchased a new stake in Pfizer during the second quarter worth about $596,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Citigroup lowered their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday. Evercore ISI raised Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Guggenheim reduced their target price on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Trading Down 0.3 %

Shares of NYSE PFE opened at $26.79 on Wednesday. The company has a market cap of $151.79 billion, a price-to-earnings ratio of 36.20, a P/E/G ratio of 0.64 and a beta of 0.64. The business has a fifty day simple moving average of $26.18 and a 200-day simple moving average of $27.91. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same period last year, the business earned ($0.17) EPS. The business’s quarterly revenue was up 31.2% on a year-over-year basis. Sell-side analysts predict that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.42%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio is 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.